Find a Provider

Selina M. Luger, MD

Selina M. Luger, MD Physician

Director, Leukemia Program
Professor of Medicine at the Hospital of the University of Pennsylvania

Languages spoken:

  • French

Dr. Luger is a Penn Medicine employed physician.

About Dr. Selina M. Luger

Recognized by America's Top Doctors, 2013-14

Recognized by Best Doctors in America 2009-2010, 2011-2012, 2013-2014

Clinical Specialties


  • Medicine
    • Hematology
    • Medical Oncology

Programs & Services:

  • Cancer
    • Bone Marrow Transplant and Stem Cell Transplant Program
    • Leukemia
    • Lymphoma
    • Multiple Myeloma
  • Hematology
    • Classical (Non-Malignant) Hematology Program

Board Certification:

  • Hematology, 1994

Conditions & Treatments:

  • acute leukemia
  • Acute Lymphocytic Leukemia in Adults (ALL)
  • Acute Myeloid Leukemia (AML)
  • allogeneic transplant
  • Blood Cancer
  • cancer - non-surgical treatment
  • chronic leukemia
  • Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  • Chronic Myeloid Leukemia (CML)
  • Hodgkin Lymphoma
  • Hodgkin's lymphoma
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Myeloproliferative Neoplams (MPN)
  • Non-Hodgkin Lymphoma
  • non-Hodgkin's lymphoma
  • Waldenstrom macroglobulinemia

Clinical Interests

hematologic malignancies, leukemia, AML, ALL, CML, myelodysplastic syndrome, MDS, myeloproliferative disorders, stem cell transplantation, bone marrow transplant

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: McGill University
Residency: Presbyterian University Hospital
Fellowship: Hospital of the University of Pennsylvania


American Society of Clinical Oncology, National American Society of Hematology, National American Society of Hematology, National American Society of Hematology, National Center for International Blood and Marrow Transplant Research (CIBMTR), International Eastern Cooperative Oncology Group, National Royal College of Physicians and Surgeons of Canada, National


Dr. Luger is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Research Interests:

Leukemia, myelodysplastic syndrome, myeloproliferative disorders

Selected Publications:

DiPersio JF1, Erba HP2, Larson RA3, Luger SM4, Tallman MS5, Brill JM6, Vuagniaux G7, Rouits E7, Sorensen JM6, Zanna C7.: Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia-Results of a Phase I Dose-Escalation Study. Clin Lymphoma Myeloma Leuk : 2015.

Orlowski RJ1, Mangan JK, Luger SM.: Approach to patients with primary refractory acute myeloid leukemia. Curr Opin Hematol : 2015.

Singh N1, Qayyum S, Wasik MA, Luger SM.: Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy. Am J Hematol : 2015.

Sehgal AR1, Gimotty PA2, Zhao J3, Hsu JM4, Daber R3, Morrissette JD5, Luger SM6, Loren AW4, Carroll M7.: DNMT3A mutational status affects the results of dose-escalated induction therapy in acute myelogenous leukemia. Clin Cancer Res : 2015.

Perez-Andreu V1, Roberts KG2, Xu H3, Smith C1, Zhang H1, Yang W1, Harvey RC4, Payne-Turner D2, Devidas M5, Cheng IM6, Carroll WL7, Heerema NA8, Carroll AJ9, Raetz EA10, Gastier-Foster JM11, Marcucci G12, Bloomfield CD12, Mrózek K12, Kohlschmidt J13, Stock W14, Kornblau SM15, Konopleva M16, Paietta E17, Rowe JM18, Luger SM19, Tallman MS20, Dean M21, Burchard EG22, Torgerson DG22, Yue F23, Wang Y23, Pui CH24, Jeha S24, Relling MV1, Evans WE1, Gerhard DS25, Loh ML26, Willman CL6, Hunger SP27, Mullighan CG2, Ya: A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood. : 2015.

Bagley SJ1, Sehgal AR2, Gill S3, Frey NV3, Hexner EO3, Loren AW3, Mangan JK3, Porter DL3, Stadtmauer EA3, Reshef R3, Luger SM3.: Acute Cholecystitis Is a Common Complication after Allogeneic Stem Cell Transplantation and Is Associated with the Use of Total Parenteral Nutrition. Biol Blood Marrow Transplant : 2014.

Li S, Garrett-Bakelman F, Perl AE, Luger SM, Zhang C, To BL, Lewis ID, Brown AL, D'Andrea RJ, Ross ME, Levine R, Carroll M, Melnick A, Mason CE.: Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol : 2014.

Reshef Ran, Hexner Elizabeth O, Loren Alison W, Frey Noelle V, Stadtmauer Edward A, Luger Selina M, Mangan James K, Gill Saar I, Vassilev Pavel, Lafferty Kathryn A, Smith Jacqueline, Van Deerlin Vivianna M, Mick Rosemarie, Porter David L: Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation : 2014.

Fielding Adele K, Rowe Jacob M, Buck Georgina, Foroni Letizia, Gerrard Gareth, Litzow Mark R, Lazarus Hillard, Luger Selina M, Marks David I, McMillan Andrew K, Moorman Anthony V, Patel Bella, Paietta Elisabeth, Tallman Martin S, Goldstone Anthony H: UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood 123 (6): 843-50,2014.

Hexner Elizabeth, Roboz Gail, Hoffman Ron, Luger Selina, Mascarenhas John, Carroll Martin, Clementi Regina, Bensen-Kennedy Debra, Moliterno Alison: Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. British journal of haematology 164 (1): 83-93,2014.

Academic Contact Info

Perelman Center 2 West
34th and Civic Center Blvd

Philadelphia, PA 19104
Phone: (215) 614-1847
Fax: (215) 662-4064
Patient appointments: 800-789-PENN (7366)

Related Links